Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center

Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions

“…Although currently, bypass surgery appears to remain the first-line option for in-stent occlusion treatment, in the near future, new devices such as atherectomy devices, drug-eluting stents, drug-coating balloons, or their combination are expected to provide better alternatives. [22][23][24][25] Limitations. There are several limitations in this study.…”

Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial)

“…Study/first author Devices Follow-up Lesions (n) Freedom from TLR Primary patency Zilver-PTX 13 DES 1 year 108 81% 79% RELINE study 12 Viabahn covered stent 1 year 39 80% 74% PTA 1 year 44 42% 28% Werner et al 7 Brachytherapy 1 year 90 NS 80% Dick et al 6 Cutting balloon 6 months 17 59% 35% PTA 6 months 22 64% 27% Shammas et al 3 Directional atherectomy 1 year 41 66% NS Trentmann et al 4 Directional atherectomy 1 year 35 NS 25% Zeller et al 5 Directional atherectomy 1 year 43 53% 54% Shammas et al 8 Laser atherectomy þ PTA 1 year 40 49% NS Yeo et al 9 Laser atherectomy þ PTA 1 year 22 77% NS Excite ISR study 11 Laser atherectomy þ PTA 6 months 169 73.5% NS PTA 6 months 81 51.8% NS Laird et al 10 Laser atherectomy þ heparin coated stent 1 year 27 83% 48% Van den Berg et al 26 FP ISR. In 2012, Laird et al 10 evaluated laser atherectomy with heparin coated stent grafts for FP ISR repair.…”

Laser atherectomy and drug‐coated balloons for the treatment of femoropopliteal in‐stent restenosis: 2‐Year outcomes

“…9 Drug coated balloon (DCB) angioplasty has been one of the most well-studied methods to treat FP-ISR with a number of studies showing 1-year superiority compared to BA, [10][11][12][13] however the ability to treat long-segment FP-ISR and the ability to sustain patency over the long term have been viewed as a limitation of DCB angioplasty. 14,15 Debulking with atherectomy devices and especially laser atherectomy (LA) may play a role in the treatment of FP-ISR [16][17][18][19][20][21][22][23] However, the combination of debulking with an antirestenotic agent (paclitaxel) has the potential to further improve the outcomes of FP-ISR by combining vessel preparation and maximum paclitaxel effectiveness. 1,2 Previous studies have linked the combination of DCB and LA superior results compared to LA + BA for 1-year outcomes.…”